View Future GrowthHistogen 過去の業績過去 基準チェック /06Histogenの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Sep 2023最近の業績更新Reported Earnings • May 13First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.14 loss in 1Q 2021)First quarter 2022 results: US$0.013 loss per share (up from US$0.14 loss in 1Q 2021). Revenue: US$3.76m (up US$3.32m from 1Q 2021). Net loss: US$673.0k (loss narrowed 84% from 1Q 2021). Over the next year, revenue is expected to shrink by 100% compared to a 25% growth forecast for the industry in the US.Reported Earnings • Mar 13Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.39 loss per share (up from US$2.08 loss in FY 2020). Net loss: US$15.0m (loss narrowed 20% from FY 2020). Products in clinical trials Phase I: 3 Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US.Reported Earnings • May 16First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.55 loss in 1Q 2020)First quarter 2021 results: Net loss: US$4.27m (loss widened 132% from 1Q 2020).Reported Earnings • Mar 16Full year 2020 earnings released: US$2.08 loss per share (vs US$0.89 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$2.06m (down 82% from FY 2019). Net loss: US$18.8m (loss widened US$15.8m from FY 2019). Products in clinical trials Phase I: 2すべての更新を表示Recent updatesお知らせ • Apr 19Histogen Inc. Filed for BankruptcyHistogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of California on April 18, 2024. The debtor listed its assets in the range of $1 million to $10 million and liabilities in the range of $0.05 million to $0.10 million. The debtor is represented by Eric D. Goldberg of DLA Piper LLP (US) and Armanino LLP as financial advisor as its legal counsel.お知らせ • Jan 05Histogen Inc. Files Form 15Histogen Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.お知らせ • Oct 06Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite IndexHistogen, Inc. has been removed from NASDAQ Composite Index .お知らせ • Sep 27Nasdaq To File A Form 25-NSE with the SEC, To Remove Histogen's Securities from Listing and RegistrationOn September 18, 2023, Histogen Inc. (the “Company”) previously announced that its board of directors (the “Board”) approved a plan of liquidation and dissolution of the Company (the “Plan of Dissolution”), subject to approval by the Company’s stockholders. The Company also announced that it had discontinued all clinical development programs and implemented a reduction in its workforce, including the termination of all employees except for two remaining employees effective September 30, 2023 (“Workforce Reduction”). In light of the Plan of Dissolution and Workforce Reduction, the Company was notified on September 26, 2023 by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, trading of the Company’s common stock will be suspended from trading at the opening of business on October 5, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel to address the deficiencies and present a plan to regain compliance. The Company does not plan to request a hearing and, therefore, expects that trading in the Company's stock will be suspended upon the opening of business on October 5, 2023. Thereafter, Nasdaq will file a Form 25-NSE with the SEC, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. Nasdaq has not specified the exact date on which the Form 25-NSE will be filed.お知らせ • Sep 22Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI IndexHistogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Indexお知らせ • Sep 20+ 1 more updateHistogen Inc. Announces Executive ChangesOn September 18, 2023, in connection with the approval by the board of directors of Histogen Inc. of the plan of liquidation and dissolution of the Company Steven J. Mento, Ph.D., the Company’s Chief Executive Officer terminated from all positions of employment with the Company, effective as of September 30, 2023. On September 18, 2023, Susan A. Knudson, the Company’s Executive Vice President, Chief Operating Officer, Chief Financial Officer, Secretary, and principal financial officer, was appointed to the additional position of Chief Executive Officer, and was designated as the Company’s principal executive officer, in each case effective as of October 1, 2023 (the “Executive Employment Date”). Ms. Knudson will continue to serve as the Company’s Chief Financial Officer, Secretary and principal financial officer. Ms. Knudson, 59, has served as the Company’s Executive Vice President, Chief Operations Officer and Chief Financial Officer since March 2023. Ms. Knudson served as the Company’s Executive Vice President and Chief Financial Officer from May 2020 to March 2023. Previously, Ms. Knudson served as Senior Vice President, Chief Financial Officer at Pfenex Inc., a biopharmaceutical company, from February 2018 until November 2019. From 2009 to 2017, Ms. Knudson held various roles at Neothetics Inc., a specialty pharmaceutical company, including Chief Financial Officer from 2014 to 2017 and Vice President of Finance and Administration from 2009 to 2014. Prior to joining Neothetics, Ms. Knudson served as Senior Director of Finance and Administration at Avera Pharmaceuticals, a pharmaceutical company, from May 2002 to January 2009. Prior to May 2002, Ms. Knudson served as Director of Finance and Administration at MD Edge Inc., a medical communications company, from October 2000 to April 2002. Prior to joining MD Edge, Ms. Knudson served as Assistant Director of Accounting at Isis Pharmaceuticals, a pharmaceutical company, from April 2000 to October 2000. Ms. Knudson has also held senior positions at CombiChem, General Atomics and Deloitte & Touche. Ms. Knudson holds a B.A. in Accounting from the University of San Diego.お知らせ • Sep 19Histogen Intends to File Certificate of Dissolution, Delist its Shares of Common Stock from The Nasdaq Capital MarketHistogen Inc. announced that its board of directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (‘Plan of Dissolution’) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of September. ‘The Board of Directors and management devoted substantial time and effort in identifying and pursuing various opportunities, but we were unable to complete a transaction that would allow us the potential to enhance stockholder value,’ stated Steven J. Mento, Ph.D., President and Chief Executive Officer of Histogen. On September 18, 2023, Histogen’s board of directors approved the liquidation and dissolution of the company pursuant to the Plan of Dissolution, subject to stockholder approval. The company intends to call a special meeting of its stockholders in the fourth quarter of 2023 to seek approval of the Plan of Dissolution and will file proxy materials with the Securities and Exchange Commission (‘SEC’) as soon as practicable. The Plan of Dissolution contemplates an orderly wind down of Histogen’s business and operations. If Histogen’s stockholders approve the Plan of Dissolution, Histogen intends to file a certificate of dissolution, delist its shares of common stock from The Nasdaq Capital Market, satisfy or resolve its remaining liabilities and obligations, including but not limited to contingent liabilities and claims and costs associated with the dissolution, make reasonable provisions for unknown claims and liabilities, attempt to convert all of its remaining assets into cash, and make distributions to its stockholders of any remaining cash available for distribution based upon their proportionate ownership at the time of the filing of the certificate of dissolution, subject to applicable legal requirements. Upon the filing of the certificate of dissolution, Histogen intends to cease trading in its common stock, close its stock transfer books and discontinue recording transfers of shares of its capital stock, in accordance with applicable law. Histogen currently expects that its existing capital resources together with the anticipated net proceeds from any sale of pipeline assets will enable it to meet its remaining liabilities and obligations with sufficient reserves. The amount actually distributable, however, may vary substantially from any estimate provided by the company based on a number of factors.お知らせ • Jun 06Histogen Receives Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(2)On June 5, 2023, Histogen Inc. received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between April 21, 2023, through June 2, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until December 4, 2023 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). In order to regain compliance with Nasdaq’s minimum bid price requirement, the Company’s common stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the Compliance Period. In the event the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for additional time to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary. If the Company meets these requirements, the Company may be granted an additional 180 calendar days to regain compliance. However, if it appears to Nasdaq that the Company will be unable to cure the deficiency, or if the Company is not otherwise eligible for the additional cure period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company’s compliance with the other listing requirements of The Nasdaq Capital Market. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other listing criteria of The Nasdaq Capital Market.お知らせ • Jan 04Histogen Inc. Hires Alfred P. Spada as Chief Scientific OfficerHistogen Inc. announced the appointment of Alfred P. Spada Ph.D. as Chief Scientific Officer. Alfred P. Spada, Ph. D. is a seasoned veteran of pharmaceutical discovery and development with over 35 years of combined experience in large Pharma and Biotech. Dr. Spada most recently served as President and CEO of Aya Biosciences focused on the discovery and development of novel therapies for the treatment of severe neuropsychiatric disorders where he identified the company’s orally active clinical candidate and completed necessary IND-enabling studies to position the asset for clinical evaluation. Prior to joining Aya Biosciences, Dr. Spada was co-founder, EVP of R&D and CSO of Conatus Pharmaceuticals until its merger with Histogen in May 2020. At Conatus, Dr. Spada was responsible for the management of all preclinical and safety activities and assisted in the generation of IND packages and presentations to support the company’s clinical assets. Prior to Conatus, Dr. Spada was the VP of Preclinical and Pharmaceutical Development at Idun Pharmaceuticals until its acquisition by Pfizer in 2005 and prior to Idun, the Director of Chemistry in the United States for Rhone-Poulenc Rorer and Aventis Pharmaceuticals. Dr. Spada received his Ph.D. in organic chemistry from MIT and conducted post-doctoral studies at Yale. Dr. Spada holds a BS in chemistry from Worcester Polytechnic Institute.Seeking Alpha • Aug 12Histogen stock down 8% after Q2 loss, on track for six-day losing streakShares of micro-cap clinical-stage therapeutics company Histogen (NASDAQ:HSTO) fell 8% to $1.95 in Friday afternoon trading, after the company reported a quarterly loss. The stock has been on a downward trend lately and, if today's losses hold, would post a sixth straight session in the red. From the close of Aug. 4 to yesterday, it has fallen 32%. San Diego, Calif.-based HSTO is advancing three clinical programs in hair growth, dermal fillers and joint cartilage repair. HSTO after hours on Thursday posted Q2 GAAP EPS of -$1.55. The company believes its existing cash and cash equivalents and cash inflow from operations would be sufficient to meet its anticipated cash needs through Dec. 2023. It closed a $5M private financing in July.Seeking Alpha • Jul 12Histogen announces pricing of $5M private placementA clinical-stage therapeutics company, Histogen (NASDAQ:HSTO) has entered into a securities purchase agreement with a single healthcare-focused institutional investor to issue 1.77M shares of common stock, Series A warrants to purchase additional 1.77M and Series B warrants to purchase up to an aggregate of 1.77M at a purchase price of $2.818 per share of common stock . Expected gross proceeds to Histogen of ~$5M. Closing is expected to occur on or about July 15, 2022.Reported Earnings • May 13First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.14 loss in 1Q 2021)First quarter 2022 results: US$0.013 loss per share (up from US$0.14 loss in 1Q 2021). Revenue: US$3.76m (up US$3.32m from 1Q 2021). Net loss: US$673.0k (loss narrowed 84% from 1Q 2021). Over the next year, revenue is expected to shrink by 100% compared to a 25% growth forecast for the industry in the US.Price Target Changed • Apr 27Price target decreased to US$2.25Down from US$2.70, the current price target is an average from 2 analysts. New target price is 1,013% above last closing price of US$0.20. Stock is down 82% over the past year. The company posted a net loss per share of US$0.39 last year.Reported Earnings • Mar 13Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.39 loss per share (up from US$2.08 loss in FY 2020). Net loss: US$15.0m (loss narrowed 20% from FY 2020). Products in clinical trials Phase I: 3 Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US.分析記事 • Dec 02We're A Little Worried About Histogen's (NASDAQ:HSTO) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Reported Earnings • May 16First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.55 loss in 1Q 2020)First quarter 2021 results: Net loss: US$4.27m (loss widened 132% from 1Q 2020).Reported Earnings • Mar 16Full year 2020 earnings released: US$2.08 loss per share (vs US$0.89 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$2.06m (down 82% from FY 2019). Net loss: US$18.8m (loss widened US$15.8m from FY 2019). Products in clinical trials Phase I: 2Executive Departure • Mar 11Independent Director has left the companyOn the 10th of March, Yizhuo Zhang's tenure as Independent Director ended after 4.5 years in the role. As of December 2020, Yizhuo personally held 600.98k shares (US$456k worth at the time). A total of 5 executives have left over the last 12 months.Is New 90 Day High Low • Feb 11New 90-day high: US$1.72The company is up 17% from its price of US$1.47 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: US$1.19The company is down 28% from its price of US$1.65 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.Is New 90 Day High Low • Dec 01New 90-day low: US$1.31The company is down 32% from its price of US$1.92 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period.収支内訳Histogen の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:HSTO.Q 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Sep 230-129030 Jun 230-129031 Mar 230-149031 Dec 224-119030 Sep 224-119030 Jun 224-128031 Mar 224-118031 Dec 211-158030 Sep 212-158030 Jun 211-158031 Mar 212-218031 Dec 202-197030 Sep 203-187030 Jun 203-156031 Mar 204-96031 Dec 1911-36030 Sep 1910-25031 Dec 182-63031 Dec 1710230質の高い収益: HSTO.Qが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: HSTO.Qの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: HSTO.Qの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: HSTO.Qの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: HSTO.Qの過去 1 年間の収益成長がBiotechs業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: HSTO.Qは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/04/08 08:39終値2025/04/04 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Histogen Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関John NewmanCanaccord GenuityDouglas TsaoH.C. Wainwright & Co.
Reported Earnings • May 13First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.14 loss in 1Q 2021)First quarter 2022 results: US$0.013 loss per share (up from US$0.14 loss in 1Q 2021). Revenue: US$3.76m (up US$3.32m from 1Q 2021). Net loss: US$673.0k (loss narrowed 84% from 1Q 2021). Over the next year, revenue is expected to shrink by 100% compared to a 25% growth forecast for the industry in the US.
Reported Earnings • Mar 13Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.39 loss per share (up from US$2.08 loss in FY 2020). Net loss: US$15.0m (loss narrowed 20% from FY 2020). Products in clinical trials Phase I: 3 Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US.
Reported Earnings • May 16First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.55 loss in 1Q 2020)First quarter 2021 results: Net loss: US$4.27m (loss widened 132% from 1Q 2020).
Reported Earnings • Mar 16Full year 2020 earnings released: US$2.08 loss per share (vs US$0.89 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$2.06m (down 82% from FY 2019). Net loss: US$18.8m (loss widened US$15.8m from FY 2019). Products in clinical trials Phase I: 2
お知らせ • Apr 19Histogen Inc. Filed for BankruptcyHistogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of California on April 18, 2024. The debtor listed its assets in the range of $1 million to $10 million and liabilities in the range of $0.05 million to $0.10 million. The debtor is represented by Eric D. Goldberg of DLA Piper LLP (US) and Armanino LLP as financial advisor as its legal counsel.
お知らせ • Jan 05Histogen Inc. Files Form 15Histogen Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.
お知らせ • Oct 06Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite IndexHistogen, Inc. has been removed from NASDAQ Composite Index .
お知らせ • Sep 27Nasdaq To File A Form 25-NSE with the SEC, To Remove Histogen's Securities from Listing and RegistrationOn September 18, 2023, Histogen Inc. (the “Company”) previously announced that its board of directors (the “Board”) approved a plan of liquidation and dissolution of the Company (the “Plan of Dissolution”), subject to approval by the Company’s stockholders. The Company also announced that it had discontinued all clinical development programs and implemented a reduction in its workforce, including the termination of all employees except for two remaining employees effective September 30, 2023 (“Workforce Reduction”). In light of the Plan of Dissolution and Workforce Reduction, the Company was notified on September 26, 2023 by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, trading of the Company’s common stock will be suspended from trading at the opening of business on October 5, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel to address the deficiencies and present a plan to regain compliance. The Company does not plan to request a hearing and, therefore, expects that trading in the Company's stock will be suspended upon the opening of business on October 5, 2023. Thereafter, Nasdaq will file a Form 25-NSE with the SEC, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. Nasdaq has not specified the exact date on which the Form 25-NSE will be filed.
お知らせ • Sep 22Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI IndexHistogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index
お知らせ • Sep 20+ 1 more updateHistogen Inc. Announces Executive ChangesOn September 18, 2023, in connection with the approval by the board of directors of Histogen Inc. of the plan of liquidation and dissolution of the Company Steven J. Mento, Ph.D., the Company’s Chief Executive Officer terminated from all positions of employment with the Company, effective as of September 30, 2023. On September 18, 2023, Susan A. Knudson, the Company’s Executive Vice President, Chief Operating Officer, Chief Financial Officer, Secretary, and principal financial officer, was appointed to the additional position of Chief Executive Officer, and was designated as the Company’s principal executive officer, in each case effective as of October 1, 2023 (the “Executive Employment Date”). Ms. Knudson will continue to serve as the Company’s Chief Financial Officer, Secretary and principal financial officer. Ms. Knudson, 59, has served as the Company’s Executive Vice President, Chief Operations Officer and Chief Financial Officer since March 2023. Ms. Knudson served as the Company’s Executive Vice President and Chief Financial Officer from May 2020 to March 2023. Previously, Ms. Knudson served as Senior Vice President, Chief Financial Officer at Pfenex Inc., a biopharmaceutical company, from February 2018 until November 2019. From 2009 to 2017, Ms. Knudson held various roles at Neothetics Inc., a specialty pharmaceutical company, including Chief Financial Officer from 2014 to 2017 and Vice President of Finance and Administration from 2009 to 2014. Prior to joining Neothetics, Ms. Knudson served as Senior Director of Finance and Administration at Avera Pharmaceuticals, a pharmaceutical company, from May 2002 to January 2009. Prior to May 2002, Ms. Knudson served as Director of Finance and Administration at MD Edge Inc., a medical communications company, from October 2000 to April 2002. Prior to joining MD Edge, Ms. Knudson served as Assistant Director of Accounting at Isis Pharmaceuticals, a pharmaceutical company, from April 2000 to October 2000. Ms. Knudson has also held senior positions at CombiChem, General Atomics and Deloitte & Touche. Ms. Knudson holds a B.A. in Accounting from the University of San Diego.
お知らせ • Sep 19Histogen Intends to File Certificate of Dissolution, Delist its Shares of Common Stock from The Nasdaq Capital MarketHistogen Inc. announced that its board of directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (‘Plan of Dissolution’) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of September. ‘The Board of Directors and management devoted substantial time and effort in identifying and pursuing various opportunities, but we were unable to complete a transaction that would allow us the potential to enhance stockholder value,’ stated Steven J. Mento, Ph.D., President and Chief Executive Officer of Histogen. On September 18, 2023, Histogen’s board of directors approved the liquidation and dissolution of the company pursuant to the Plan of Dissolution, subject to stockholder approval. The company intends to call a special meeting of its stockholders in the fourth quarter of 2023 to seek approval of the Plan of Dissolution and will file proxy materials with the Securities and Exchange Commission (‘SEC’) as soon as practicable. The Plan of Dissolution contemplates an orderly wind down of Histogen’s business and operations. If Histogen’s stockholders approve the Plan of Dissolution, Histogen intends to file a certificate of dissolution, delist its shares of common stock from The Nasdaq Capital Market, satisfy or resolve its remaining liabilities and obligations, including but not limited to contingent liabilities and claims and costs associated with the dissolution, make reasonable provisions for unknown claims and liabilities, attempt to convert all of its remaining assets into cash, and make distributions to its stockholders of any remaining cash available for distribution based upon their proportionate ownership at the time of the filing of the certificate of dissolution, subject to applicable legal requirements. Upon the filing of the certificate of dissolution, Histogen intends to cease trading in its common stock, close its stock transfer books and discontinue recording transfers of shares of its capital stock, in accordance with applicable law. Histogen currently expects that its existing capital resources together with the anticipated net proceeds from any sale of pipeline assets will enable it to meet its remaining liabilities and obligations with sufficient reserves. The amount actually distributable, however, may vary substantially from any estimate provided by the company based on a number of factors.
お知らせ • Jun 06Histogen Receives Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(2)On June 5, 2023, Histogen Inc. received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between April 21, 2023, through June 2, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until December 4, 2023 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). In order to regain compliance with Nasdaq’s minimum bid price requirement, the Company’s common stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the Compliance Period. In the event the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for additional time to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary. If the Company meets these requirements, the Company may be granted an additional 180 calendar days to regain compliance. However, if it appears to Nasdaq that the Company will be unable to cure the deficiency, or if the Company is not otherwise eligible for the additional cure period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company’s compliance with the other listing requirements of The Nasdaq Capital Market. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other listing criteria of The Nasdaq Capital Market.
お知らせ • Jan 04Histogen Inc. Hires Alfred P. Spada as Chief Scientific OfficerHistogen Inc. announced the appointment of Alfred P. Spada Ph.D. as Chief Scientific Officer. Alfred P. Spada, Ph. D. is a seasoned veteran of pharmaceutical discovery and development with over 35 years of combined experience in large Pharma and Biotech. Dr. Spada most recently served as President and CEO of Aya Biosciences focused on the discovery and development of novel therapies for the treatment of severe neuropsychiatric disorders where he identified the company’s orally active clinical candidate and completed necessary IND-enabling studies to position the asset for clinical evaluation. Prior to joining Aya Biosciences, Dr. Spada was co-founder, EVP of R&D and CSO of Conatus Pharmaceuticals until its merger with Histogen in May 2020. At Conatus, Dr. Spada was responsible for the management of all preclinical and safety activities and assisted in the generation of IND packages and presentations to support the company’s clinical assets. Prior to Conatus, Dr. Spada was the VP of Preclinical and Pharmaceutical Development at Idun Pharmaceuticals until its acquisition by Pfizer in 2005 and prior to Idun, the Director of Chemistry in the United States for Rhone-Poulenc Rorer and Aventis Pharmaceuticals. Dr. Spada received his Ph.D. in organic chemistry from MIT and conducted post-doctoral studies at Yale. Dr. Spada holds a BS in chemistry from Worcester Polytechnic Institute.
Seeking Alpha • Aug 12Histogen stock down 8% after Q2 loss, on track for six-day losing streakShares of micro-cap clinical-stage therapeutics company Histogen (NASDAQ:HSTO) fell 8% to $1.95 in Friday afternoon trading, after the company reported a quarterly loss. The stock has been on a downward trend lately and, if today's losses hold, would post a sixth straight session in the red. From the close of Aug. 4 to yesterday, it has fallen 32%. San Diego, Calif.-based HSTO is advancing three clinical programs in hair growth, dermal fillers and joint cartilage repair. HSTO after hours on Thursday posted Q2 GAAP EPS of -$1.55. The company believes its existing cash and cash equivalents and cash inflow from operations would be sufficient to meet its anticipated cash needs through Dec. 2023. It closed a $5M private financing in July.
Seeking Alpha • Jul 12Histogen announces pricing of $5M private placementA clinical-stage therapeutics company, Histogen (NASDAQ:HSTO) has entered into a securities purchase agreement with a single healthcare-focused institutional investor to issue 1.77M shares of common stock, Series A warrants to purchase additional 1.77M and Series B warrants to purchase up to an aggregate of 1.77M at a purchase price of $2.818 per share of common stock . Expected gross proceeds to Histogen of ~$5M. Closing is expected to occur on or about July 15, 2022.
Reported Earnings • May 13First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.14 loss in 1Q 2021)First quarter 2022 results: US$0.013 loss per share (up from US$0.14 loss in 1Q 2021). Revenue: US$3.76m (up US$3.32m from 1Q 2021). Net loss: US$673.0k (loss narrowed 84% from 1Q 2021). Over the next year, revenue is expected to shrink by 100% compared to a 25% growth forecast for the industry in the US.
Price Target Changed • Apr 27Price target decreased to US$2.25Down from US$2.70, the current price target is an average from 2 analysts. New target price is 1,013% above last closing price of US$0.20. Stock is down 82% over the past year. The company posted a net loss per share of US$0.39 last year.
Reported Earnings • Mar 13Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.39 loss per share (up from US$2.08 loss in FY 2020). Net loss: US$15.0m (loss narrowed 20% from FY 2020). Products in clinical trials Phase I: 3 Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US.
分析記事 • Dec 02We're A Little Worried About Histogen's (NASDAQ:HSTO) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Reported Earnings • May 16First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.55 loss in 1Q 2020)First quarter 2021 results: Net loss: US$4.27m (loss widened 132% from 1Q 2020).
Reported Earnings • Mar 16Full year 2020 earnings released: US$2.08 loss per share (vs US$0.89 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$2.06m (down 82% from FY 2019). Net loss: US$18.8m (loss widened US$15.8m from FY 2019). Products in clinical trials Phase I: 2
Executive Departure • Mar 11Independent Director has left the companyOn the 10th of March, Yizhuo Zhang's tenure as Independent Director ended after 4.5 years in the role. As of December 2020, Yizhuo personally held 600.98k shares (US$456k worth at the time). A total of 5 executives have left over the last 12 months.
Is New 90 Day High Low • Feb 11New 90-day high: US$1.72The company is up 17% from its price of US$1.47 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: US$1.19The company is down 28% from its price of US$1.65 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.
Is New 90 Day High Low • Dec 01New 90-day low: US$1.31The company is down 32% from its price of US$1.92 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period.